IPASS
Iressa Pan-Asia Study
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 1,217 Asian, never/light-smoker patients with advanced lung adenocarcinoma, gefitinib improved progression-free survival in the EGFR-mutation-positive subgroup compared with carboplatin + paclitaxel.
N
1217
Disegno
Open-label RCT
Esito
Progression-free survival
Rilevanza
1
RisultatoOverall PFS HR 0.74. EGFR-mutated: HR 0.48; EGFR wild-type: HR 2.85 — striking qualitative interaction.
Mok TS, et al. N Engl J Med. 2009;361(10):947-957. 10.1056/NEJMoa0810699
Discussione e critica
Foundational trial of precision oncology — mandated EGFR-mutation testing before first-line therapy in advanced NSCLC.